“We believe a national RSV program is needed so all infants born in Australia have access to Beyfortus. A national program for next year’s RSV season will make it easier for parents and healthcare professionals to discuss infant eligibility, no matter where the child is born," said Regis Launay, the general manager of vaccines for Sanofi Australia and New Zealand. …
More states announce RSV programs as families call for national action
March 26, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News